Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

globenewswire.com - Nxera Pharma - Nxera Pharma's Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition
Nxera Pharma's Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition
GlobeNewswire

NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with Neurocrine Nxera to receive a US$10 million milestone…

indianexpress.com - Nischai Vats - Trump's Iran sanctions: Why India's rice, pharma exports are at risk
Trump's Iran sanctions: Why India's rice, pharma exports are at risk
The Indian Express

3 min read New Delhi Make us preferred source on Google The US has launched a sweeping new campaign to isolate Iran economically, warning foreign companies and countries that continue doing business with Tehran that they could face sanctions and…

newswire.ca - Groupe LSL PHARMA INC. - LSL PHARMA GROUP REPORTS RECORD REVENUES AND SECOND QUARTER 2026 RESULTS
LSL PHARMA GROUP REPORTS RECORD REVENUES AND SECOND QUARTER 2026 RESULTS
CNW

Record quarterly revenues from both the CMO and Private Label business segments; Results include the commercial launch of the new eye-drops portfolio; Health Canada Remediation plan and production capacity scale-up at Steri-Med progressing as…

thehindu.com - The Hindu Bureau - Natco Pharma invests $14mn in biotech firm eGenesis; total investment at $22mn
Natco Pharma invests $14mn in biotech firm eGenesis; total investment at $22mn
The Hindu

Generic drugmaker Natco Pharma is investing an additional $14 million in U.S.-based biotechnology company eGenesis, which is developing genetically engineered, human-compatible organs for transplantation. The latest investment will be made through…

law360.com - George Woolston - Drugstores Beat Sun Pharma's $10M Racketeering Suit
Drugstores Beat Sun Pharma's $10M Racketeering Suit
Law360

A New Jersey federal judge threw out Sun Pharmaceutical Industries Inc.'s suit against a group of pharmacies alleging they engaged in a criminal, years-long racketeering scheme that resulted in it paying... To view the full article, register now.

thehindu.com - The Hindu Bureau - Dr. Reddy's CDMO arm Aurigene inks long-term manufacturing pact with global pharma major
Dr. Reddy's CDMO arm Aurigene inks long-term manufacturing pact with global pharma major
The Hindu

Contract research, development and manufacturing organisation Aurigene Pharmaceutical Services, a subsidiary of Dr. Reddy's Laboratories, has entered into a long-term manufacturing and supply agreement (MSA) with a leading global pharmaceutical…

thehindubusinessline.com - Natco Pharma to invest $14 million in eGenesis Inc
Natco Pharma to invest $14 million in eGenesis Inc
BusinessLine

Natco Pharma on Tuesday said it is investing $14 million (over ₹130 crore) in eGenesis Inc, a US-based biotechnology firm, through its two subsidiaries. As part of the transaction, Natco Pharma (Canada) Inc will invest $9.5 million and Natco…

marketbeat.com - NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 125,000 Shares of Stock
NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 125,000 Shares of Stock
MarketBeat

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) insider Johannes Jacob Piete Kastelein sold 125,000 shares of the firm's stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $26.91, for a…

marketbeat.com - Parkman Healthcare Partners LLC Acquires New Position in Urogen Pharma $URGN
Parkman Healthcare Partners LLC Acquires New Position in Urogen Pharma $URGN
MarketBeat

Parkman Healthcare Partners LLC acquired a new position in shares of Urogen Pharma (NASDAQ:URGN - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional…

science20.com - Hank Campbell - Navigating Vaccine Guidance
Navigating Vaccine Guidance
Science 2.0

During the Obama administration, he was concerned about vaccines causing autism and it showed when it came to guidance about swine flu vaccines. His administration banned multi-use vials because of his party's insistence that preservatives caused…

fool.com - Motley Fool Transcribing - Evogene (EVGN) Q2 2026 Earnings Call Transcript
Evogene (EVGN) Q2 2026 Earnings Call Transcript
The Motley Fool

Tuesday, Aug. 18, 2026 at 9:00 a.m. ET Chairman of the Board of Directors - Nir Nimrodi President and CEO - Ofer Haviv VP Finance - Polina Ravzin Cash and Cash Equivalents -- $9.3 million as of June 30, 2026, reflecting the company's current…

247wallst.com - Omor Ibne Ehsan - 'Give Me Anything But Tech': Jim Cramer's Bold Call on the Market's Next Big Rotation
'Give Me Anything But Tech': Jim Cramer's Bold Call on the Market's Next Big Rotation
24/7 Wall St

On CNBC's Squawk on the Street Monday morning, Jim Cramer said the tape has soured on the trade that carried the market for most of the past year. “We're defaulting to all right, give me anything but tech, give me anything but data center.

indianexpress.com - Express Global Desk - US visa appointments paused globally as Trump tightens immigration rules
US visa appointments paused globally as Trump tightens immigration rules
The Indian Express

The Donald Trump administration has paused visa appointments for applicants worldwide as the US stepped up its immigration crackdown during the President's second term. A US State Department spokesperson on Tuesday was quoted as saying by news…

fool.com - Jeff Siegel - Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off
The Motley Fool

For Madrigal Pharmaceuticals (MDGL +0.60%) stock to take off, three things need to happen: Sales of Rezdiffra need to keep growing; the drug needs to expand to patients with cirrhosis caused by metabolic dysfunction-associated steatohepatitis…

marketbeat.com - 99,181 Shares in DexCom, Inc. $DXCM Acquired by Cibc World Market Inc.
99,181 Shares in DexCom, Inc. $DXCM Acquired by Cibc World Market Inc.
MarketBeat

Cibc World Market Inc. bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 99,181…

Receive a Daily briefing on Pharma Industry News

Get Started